Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion Pharmaceuticals beat estimated earnings by 30.0%, reporting an EPS of $-0.21 versus an estimate of $-0.3. Revenue was up $30.99 million from the same period last year. During the previous ...
It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 16.2% in that time frame, outperforming the S&P 500. But investors have to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results